#1Bionomics Corporate Update Presentation Improving the Lives of Patients with Serious CNS Disorders ASX: BNO Nasdaq: BNOX June 2022 Bionomics#2SAFE HARBOR STATEMENT 2 Factors Affecting Future Performance This presentation may contain "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this presentation that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210, BNC105, BNC101 and BNC375), its licensing agreement with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing arrangements, delays or difficulties associated with conducting clinical trials, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its expectations, projections or plans will be achieved. Actual results may differ from those expectations, projections or plans due to the risks and uncertainties inherent in Bionomics business and other risks described in Bionomics' filings with the SEC. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward- looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this presentation. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation. Certain information contained in this presentation relates to, or is based on, studies, publications, surveys and other data obtained from third party sources and Bionomics' own internal estimates and research. While we believe these third-party sources to be reliable as of the date of this presentation, we have not independently verified, and make no representation as to the adequacy, fairness, accuracy or completeness of any information obtained from third party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source. Bionomics#3Bionomics Highlights Targeting Social Anxiety Disorder (SAD) and PTSD, and cognitive dysfunction associated with Alzheimer's disease, schizophrenia and other CNS disorders Lead asset: BNC210 - a negative allosteric modulator of the a7 Nicotinic Acetylcholine receptor alı BNC210: ✓ Clinical PoC in GAD¹ and FDA Fast Track designation for acute Social Anxiety Disorder (SAD) ✓ In Phase 2 PREVAIL trial for acute treatment in SAD In Phase 2b ATTUNE trial with Fast Track designation from FDA for PTSD Partnerships & Collaborations: ✓ Strategic partnership with Merck for treatment of cognitive deficits in Alzheimer's and other CNS disorders ✓ MOU with EmpathBio for feasibility assessment of EMP-01 (MDMA derivative) & BNC210 for PTSD treatment ✓ Pipeline of partnering candidates targeting potassium (Kv) and sodium (Nav) ion channels ✓ Well-capitalized balance sheet and cash runway beyond multiple potential near term value-driving milestones ✓ BNC210 IP coverage extending to late 2030's Bionomics PoC = Proof of Concept GAD= Generalized Anxiety Disorder PTSD = Post-Traumatic Stress Disorder 1. Wise et al 2020, Biological Psychiatry; Perkins et al 2021, Molecular Psychiatry 3#4Focused CNS Pipeline with Multiple Potential Catalysts on the Horizon Program BNC210 a7 receptor NAM EmpathBio MERCK Collaboration a7 receptor PAM Nav1.7/1.8 Inhibitors Candidate Kv3.1/3.2 Activators Series Lead Bionomics Indication Social Anxiety Disorder (SAD) Post-Traumatic Stress Disorder (PTSD) +MDMA derivative EMP-01 (PTSD) 2 candidates for cognitive deficits in Alzheimer's Chronic Pain Cognitive Impairment NAM = Negative Allosteric Modulator PAM = Positive Allosteric Modulator Pre-Clinical Phase 1 Phase 2 PREVAIL ATTUNE Phase 3 Memorandum of Understanding to explore combination treatment regimen for PTSD FDA Fast Track designation Status Study underway Topline Data: YE'22 Study underway Topline Data: 1H'23 Feasibility studies ongoing Phase 1 safety & biomarker studies ongoing Pending Pending 4#5Social Anxiety Disorder: Definition and Impacts SAD Represents a Significant Unmet Need Å isi Social Anxiety Disorder (SAD), or Social Phobia, is a significant and persistent fear of social and performance-related situations Includes anxiety from everyday social situations Frequently occurring episodic disorder Amongst the largest mental health conditions with lifetime prevalence affecting >31M Americans Triggers that exacerbate anxiety can occur at any time. Bionomics Work Patients may orient their careers around a narrow set of potential occupations and may struggle with job performance Relationships Friendships, family relationships, & romantic partnerships are physically draining and stressful. Moderate to severe patients often live alone Lifestyle Events like dining entertainment, and public transport, are often very distressful and/or impossible for SAD patients Daily Activities Normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee can be very challenging for SAD patients Sources: US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html NIMH. "Social Anxiety Disorder" data from 2017 National Comorbidity Survey (NCS). https://www.nimh.nih.gov/health/statistics/social-anxiety-disorder.shtml Anxiety and Depression Association of America (ADAA). "Social Anxiety Disorder - Understand the Facts" https://adaa.org/understanding-anxiety/social-anxiety-disorder 5#6Targeting a Large Segment of the Anxiety Market/Market Size No FDA-approved fast-acting medications for as-needed treatment $2,000 $1,750 $1,500 $1,250 $1,000 $750 $500 $250 $0 Bionomics BNC210 US Social Anxiety Disorder Sales ($M) 247 1,092 1,506 2029 1,662 2026 2032 2035 BNC210 could achieve $1.7B in US annual peak sales in SAD* ~7M Opportunity for BNC210 ~18M 36% of adults SAD symptoms > 10 years Sources: US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html NIMH. "Social Anxiety Disorder" data from 2017 National Comorbidity Survey (NCS). https://www.nimh.nih.gov/health/statistics/social-anxiety-disorder.shtml Anxiety and Depression Association of America (ADAA). "Social Anxiety Disorder - Understand the Facts" https://adaa.org/understanding-anxiety/social-anxiety-disorder *For forecast assumptions and methods see appendix *Based on 3rd party market analysis 31M 7.1% prevalence in adults 12.1% of adults at some point in their lives 6#7The Mechanism and Pharmacology of BNC210 Demonstrate its Advantages over Current Therapies for Anxiety Disorders and PTSD* SSRIs & SNRIS 1 BZDs ² (Off-label) BNC210 Fast Onset of Action X ✓ ✓ Not Sedating ✓ X ✓ No Withdrawal/ No Memory Abuse Potential Impairment ✓ X X ✓ X ✓ No Motor Impairment ✓ X ✓ * Potential benefits based on analysis of data from separate studies and not on results that might have been obtained from head-to-head studies. Such data may not be directly Bionomics comparable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of BNC210 compared to existing therapies or other product candidates that may be approved or are in development for the treatment of PTSD or SAD. 1. Includes Valium and certain other benzodiazepines 2. Includes Prozac and certain other SSRIs (Selective Serotonin Reuptake Inhibitors) / SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) No Suicidal Ideation X ✓ ✓ 7 8#8BNC210 is in an Ongoing Phase 2 PREVAIL Study for Acute Social Anxiety Disorder FDA FAST TRACK DESIGNATION F Compelling Rationale for BNC210 as an Acute Treatment in Social Anxiety Disorder A Bionomics FOR SAD ANTI-PANIC ANTI-ANXIETY REDUCES PERCEPTION OF THREAT FAST-ACTING UNMET NEED Single doses reduce panic symptoms & intensity in healthy volunteers experiencing a CCK-4 induced panic attack Single doses reduce amygdala activation in GAD patients performing the Emotional Faces task during fMRI Single doses reduce threat avoidance behavior in GAD patients performing a behavioral task Pharmacokinetics of reformulated BNC210 tablet are ideal for acute dosing No acute treatments are approved for SAD; represents potential for rapid path to market 8#9PTSD: A Chronic Psychiatric Disorder with Significant Morbidity and Mortality PTSD Represents a Significant Unmet Need A debilitating disorder that leads to social, occupational and interpersonal dysfunction PTSD involves flashbacks, intrusive thoughts and "nightmares PTSD causes changes in cognition, mood, arousal and reactivity PTSD results from exposure to actual or threatened death, serious injury or sexual violence Only 20-30% of PTSD patients achieve clinical remission on SoC SSRI therapy² Bionomics 1. Work Patients may orient their careers around a narrow set of potential occupations and may struggle with job performance 3. Relationships PTSD can impair trust, closeness, and communication, leading to difficulty maintaining family and romantic relationships. Lifestyle PTSD-associated poor nutrition, reduced physical activity, and increased obesity and smoking, increase risk of cardiovascular and other diseases Kilpatrick, D., Resnick, H., Milanak, M., Miller, M., Keyes, K. and Friedman, M., 2013. National Estimates of Exposure to Traumatic Events and PTSD Prevalence Using DSM-IV and DSM-5 Criteria. Journal of Traumatic Stress, 26(5), pp.537-547; 2 Mayo LM, Asratain A., Lindé J et al. Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry. 2020 Mar 15; 87(6): 538-54 2. Lee DJ, et al. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33(9):792-806. US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html Quality of Life PTSD patients avoid people, places, or environments which may trigger trauma, making daily living difficult 9#10$3,000 $2,500 $2,000 $1,500 $1,000 $500 $0 PTSD Represents a Significant Unmet Need and Market Opportunity No newly approved pharmacotherapy in almost two decades BNC210 US PTSD Sales ($M) 388 Bionomics 2,604 2,360 1,711 ill 2027 2033 2036 BNC210 could achieve $2.6B in US annual peak sales in PTSD* 2030 ~7M ~9M 75% of adults inadequately treated ² Opportunity for BNC210 ~21M 3.4% prevalence in adults 2. Only 20 to 30% of PTSD patients achieve clinical remission on SSRI therapies. US Census Bureau. https://www.census.gov/library/stories/2021/08/united-states-adult-population-grew-faster-than-nations-total-population-from-2010-to-2020.html *Based on 3rd party market analysis 8% of adults at some point in their lives¹ Unmet medical need to large patient population Advancement in care Ability to potentially achieve large market share 1. Kilpatrick, D., Resnick, H., Milanak, M., Miller, M., Keyes, K. and Friedman, M., 2013. National Estimates of Exposure to Traumatic Events and PTSD Prevalence Using DSM-IV and DSM-5 Criteria. Journal of Traumatic Stress, 26(5), pp.537-547; 2 Mayo LM, Asratain A., Lindé J et al. Elevated Anandamide, Enhanced Recall of Fear Extinction, and Attenuated Stress Responses Following Inhibition of Fatty Acid Amide Hydrolase: A Randomized, Controlled Experimental Medicine Trial. Biol Psychiatry. 2020 Mar 15; 87(6): 538-54 10#11Compelling Rationale Supporting BNC210 in Ongoing ATTUNE Phase 2b PTSD Study 11 Reduced anxious behavior in many rodent models AND reduced amygdala hyperactivity in GAD patients Therapeutic Potential in PTSD Underpinned by Mechanism & Pharmacology of BNC210 FDA FAST TRACK D A Bionomics FOR PTSD REDUCES ANXIETY ANTI- DEPRESSANT ENHANCES FEAR EXTINCTION ANTI-PANIC ACTIVITY REDUCES THREAT AVOIDANCE Antidepressant effects in rat model AND in PTSD trial at early time points Enhanced fear extinction in mice AND promoted more rapid recovery in healthy humans following panic attack (CCK-4) Reduced Number AND Intensity of Panic Symptoms in Phase 1 CCK-4 challenge Reduced threat avoidance behavior in animals (various models of threat) AND in GAD patients (Phase 2 study)#12Merck & Co Strategic Collaboration: Positive Allosteric Modulators (PAMS) of a7 Receptor a7 Receptor PAMs correct hypocholinergic states in cognitive dysfunction and impairment MERCK PARTNERSHIP Bionomics MSD Collaboration Overview 2014 agreement to develop a7 receptor PAMS targeting cognitive dysfunction associated with Alzheimer's disease, schizophrenia and other CNS conditions ✓ Merck funds all research and clinical development, and WW commercialization of any resulting products ✓ ✓ Payments received: US$20M upfront and US$10M for Phase 1 milestone Eligible to receive up to US$465M in additional milestone payments plus royalties Development Updates Two candidate a7 receptor PAMs in early-stage Phase 1 safety and biomarker clinical trials for cognitive impairment ✓ 1st compound has completed Phase 1 safety clinical trials in healthy subjects with ongoing plans for further biomarker studies 12 ✓ In 2020, a second molecule showed an improved potency profile in preclinical animal models and was advanced by Merck into Phase 1 clinical trials Wang et al. J Pharmacol Exp Ther 373:311-324, May 2020 https://pubmed.ncbi.nlm.nih.gov/32094294/ PAM = Positive allosteric modulator MSD = A tradename of Merck & Co., Inc., Kenilworth NJ USA#13CAPS-5 total severity score 50 MDMA-assisted therapy significantly reduced CAPS-V scores in PTSD patients (primary endpoint) ¹, (n=90) 40 20 10 MOU for BNC210 and MDMA Derivative (EMP-01) for Post-Traumatic Stress Disorder Joint Feasibility Assessment EMP-01 (3,4-Methylenedioxymethamphetamine) 0 MDMA-assisted therapy Placebo with therapy Baseline (T1) EmpathBio O Bionomics After session 1 (T2) ATAI LIFE SCIENCES After session 2 (T3) After session 3 (T4), primary endpoint (MDMA) derivative ✓ BNC210 + EMP-01 relieves the burden of pairing MDMA with CBT, potentially reducing the number of CBT sessions needed with MDMA treatment MOU with EmpathBio's MDMA Derivative (EMP-01) ✓ Initial collaborative framework of preclinical studies to collectively explore a combination drug treatment regimen with BNC210 and EMP-01 MDMA-assisted psychotherapy has demonstrated significant symptom improvement in PTSD patients ✓ FDA has granted a Breakthrough Therapy designation to MDMA- assisted psychotherapy ✓ EmpathBio is developing MDMA derivatives that may permit the entactogenic effects of MDMA to be separated from some of the known adverse effects ✓ To explore the possibility of a combination treatment regimen warranting clinical evaluation Note: Change in CAPS-V total severity score from T1 to T4 (P < 0.0001, d = 0.91, n = 89 (MDMA n = 46)), as a measure of the primary outcome. Primary analysis was completed using least square means from a mixed model repeated measure (MMRM) analysis model; (n=90) 1. Mitchell et al., "MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study" (2021) 13#14[] Stock, Financial and IP Snapshot iii ✓Lean operations with modest burn ✓ Well-capitalized through CY2023 ✓ A$40.4M (US$29.2M) of net cash ✓ Listed on two global exchanges ✓ Leading Significant Investors: APEIRON BVF INVESTMENT GROUP PRESIGHT Bionomics Figures as of March 30, 2022. PARTNERS L.P. MERCK ASX: BNO AUSTRALIAN SICUS LACHE Nasdaq: BNOX ✓ Research Coverage: BERENBERG PRIVATBANKIERS SEIT 1590 EVERCORE William Blair CANTOR Pitzgerald X HCW H.C.WAINWRIGHT&CO. ✓ CNS patents filed in the US and abroad ✓USA: 4 granted, 5 pending ✓ Worldwide: 4 granted, 5 pending ✓ BNC210 freedom to operate opinion 14#15Bionomics Outlook: Renewed Value-driving Trajectory Bionomics Bionomics Balanced model with multiple value-driving clinical milestones expected in the next 4 - 6 quarters E BNC210's novel rapid onset formulation granted Fast Track designation for acute treatment of SAD Established clinical proof-of-concept¹; expect Phase 2 topline data by YE'22 ( BNC210 Phase 2b ATTUNE PTSD study under way with Fast Track designation for 1H'23 topline data Tablet formulation achieves exposure projected from pharmacometric analysis Merck strategic partnership for treatment of cognitive impairment in Alzheimer's disease with two compounds in clinical development 15 Diverse early-stage pipeline of partnering prospects targeting Kv and Nav ion channels for treatment of schizophrenia and pain, respectively Well-capitalized balance sheet driven by experienced leadership SAD = Social Anxiety Disorder PTSD Post-Traumatic Stress Disorder 1. Wise T. et al., Biological Psychiatry 2020 (https://doi.org/10.1016/j.biopsych.2019.12.013); Perkins A. et al., Translational Psychiatry 2021 (https://doi.org/10.1038/s41398-020-01141-5)#16TO IMPROVE THE LIVES OF PATIENTS WITH SERIOUS CNS DISORDERS THANK YOU Bionomics